natgillin/translations-raw huggingface dataset:
I Cimzia RA kliniske studier, hvor i alt 4.049 patienter blev behandlet, svarende til 9.277 patientår, blev der, med undtagelse af non-melanomer i huden, observeret 121 maligniteter, inklusive 5 tilfælde af lymfomer.
Excluding non-melanoma of the skin, 121 malignancies including 5 cases of lymphoma were observed in the Cimzia RA clinical trials in which a total of 4,049 patients were treated, representing 9,277 patient- years.
I CINRGI-forsøget blev 186 fuldbårne eller næsten fuldbårne neonatale med hypoxisk respirationssvigt og uden lunge hypoplasi randomiseret til at modtage enten INOmax (n=97) eller nitrogengas (placebo: n=89) med en initiel koncentration på 20 ppm med fravænning til 5 ppm på 4- 24 timer med gennemsnitlig udsættelsesvarighed på 44 timer.
In the CINRGI trial, 186 term- and near-term neonates with hypoxic respiratory failure and without lung hypoplasia were randomised to receive either INOmax (n=97) or nitrogen gas (placebo; n=89) with an initial dose of 20 ppm weaning to 5 ppm in 4 to 24 hours with median duration of exposure of 44 hours.
I CINRGI-forsøget blev 186 fuldbårne eller næsten fuldbårne neonatale med hypoxisk respirationssvigt og uden lungehypoplasi randomiseret til at modtage enten INOmax (n=97) eller nitrogengas (placebo: n=89) med en initiel koncentration på 20 ppm med fravænning til 5 ppm på 4- 24 timer med gennemsnitlig udsættelsesvarighed på 44 timer.
In the CINRGI trial, 186 term- and near-term neonates with hypoxic respiratory failure and without lung hypoplasia were randomised to receive either INOmax (n=97) or nitrogen gas (placebo; n=89) with an initial dose of 20 ppm weaning to 5 ppm in 4 to 24 hours with median duration of exposure of 44 hours.
I Circadin-gruppen blev patienternes søvnlatens forkortet med 24,3 minutter over for 12,9 minutter i placebo-gruppen.
Circadin shortened patients’ reported sleep latency by 24.3 minutes vs 12.9 minutes with placebo.
I cirrosekohorten gennemgik 4 patienter med hepatocellulært karcinom en levertransplantation efter 1– 71 dages behandling.
In the cirrhosis cohort, 4 patients with hepatocellular carcinoma underwent liver transplantation after 1–71 days of treatment; 3 of the
I CLASSIC I og GAIN, blev der opnået statistisk signifikante forbedringer i total score i det sygdoms- specifikke tarm-sygdoms-spørgeskema (IBDQ) ved uge 4 for patienter randomiseret til Trudexa 80/40 mg og 160/80 mg sammenlignet med placebo, og i CHARM blev det set ved uge 26 og 56, såvel som blandt den adalimumab-behandlede-grupper sammenlignet med placebo-gruppen.
Trudexa 80/40 mg and 160/80 mg compared to placebo and was seen at weeks 26 and 56 in CHARM as well among the adalimumab treatment groups compared to the placebo group.
I CLDT600ACN04E1-studiet blev 57 patienter med tilgængelige parrede lever biopsier ved baseline og efter gennemsnitlig behandling i 260,8 uger evalueret for potentielle forandringer i lever histologi (38 HBeAg-positive og 19 HBeAg-negative patienter).
In study CLDT600ACN04E1, 57 patients with available paired liver biopsies at baseline and after mean treatment of 260.8 weeks were evaluated for changes in liver histology (38 HBeAg-positive and 19 HBeAg-negative patients).
I CLEOPATRA-studiet med metastatisk brystkræft var nadir- neutrofiltallene ens hos Perjeta-behandlede patienter og placebo-behandlede patienter.
In the CLEOPATRA trial in metastatic breast cancer, nadir neutrophil counts were similar in Perjeta-treated and placebo-treated patients.
I CLL11-studiet havde 27% (90 ud af 336) af patienterne behandlet med Gazyvaro plus chlorambucil moderat nedsat nyrefunktion (CrCl <50 ml/min).
In the CLL11 study, 27% (90 out of 336) of patients treated with Gazyvaro plus chlorambucil had moderate renal impairment (CrCl < 50 mL/min).
I COMFORT-I (MF-patienter) var den gennemsnitlige stigning i systolisk blodtryk 0-2 mmHg fra baseline for Jakavi versus et fald på 2-5 mmHg i placebo- armen.
In COMFORT-I (MF patients) the mean increase from baseline in systolic BP was 0-2 mmHg on Jakavi versus a decrease of 2-5 mmHg in the placebo arm.
I COMFORT-I opnåede 45,9% af patienterne i Jakavi-gruppen en forbedring på ≥50% i forhold til baseline i den samlede symptomscore i uge 24 (målt ved MFSAF-dagbog v2.0) sammenlignet med 5,3% af patienterne i placebogruppen (p<0,0001 med anvendelse af chi2-test).
In COMFORT-I, 45.9% subjects in the Jakavi group achieved a ≥50% improvement from baseline in the week 24 total symptom score (measured using MFSAF diary v2.0), as compared to 5.3% in the placebo group (p<0.0001 using chi-square test).
I COMFORT-II viste de gennemsnitlige værdier lille forskel mellem ruxolitinib-behandlede og kontrolbehandlede MF-patienter.
In COMFORT-II mean values showed little difference between the ruxolitinib-treated and the control-treated MF patients.
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups.
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper (0,6 % versus 0,5 % i hhv.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the Clopidogrel + ASA and the placebo + ASA groups, respectively).
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper (0,6 % versus 0,5 % i hhv. clopidogrel+ASA og placebo+ASA- gruppen).
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups, respectively).
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper (0,6 % versus 0,5 % i hhv. clopidogrel+ASA og placebo+ASA-gruppen).
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups, respectively).
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper .
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper .
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups.
I COMPAS blev der ud over serotype 6B og 14 registreret serotype 5 (2 tilfælde), 18C (4 tilfælde) og 23F (1 tilfælde) i kontrolgrupperne. de 2 kontrolgrupper med spædbørn fra studiecentrene var poolede. (3) p-værdi < 0,0001
In COMPAS, serotypes 5 (2 cases), 18C (4 cases) and 23F (1 case) were detected in control group in addition to serotypes 6B and 14. the 2 groups of control clusters of infants were pooled (3) p-value<0.0001
I COMPAS var det 66,7 % (95 % CI 21,8-85,9; 7 versus 21 tilfælde).
In COMPAS it was 66.7% (95% CI: 21.8-85.9; 7 versus 21 cases).
I COPERNICUS havde 67,5% (n = 77) i Eylea-gruppen og 68,5% (n = 50) i sham-gruppen perfunderet CRVO ved baseline.
In COPERNICUS, 67.5% (n = 77) of the Eylea group and 68.5% (n = 50) of the sham group had perfused CRVO at baseline.
I Crohns sygdom er erfaring med fornyet administration efter recidiverende sygdomstegn og symptomer begrænset og sammenlignende data vedrørende gavn versus risici på de forskellige strategier savnes.
In Crohn’s disease, experience with re-administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking.
I Crohns sygdom er erfaring med fornyet indgift efter genopdukkende sygdomstegn og symptomer begræ nset og sammenlignende data vedrørende gavn versus risici på de forskellige strategier savnes.
In Crohn’s disease, experience with re-administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking.
I Crohns sygdom er erfaring med fornyet indgift efter genopdukkende sygdomstegn og symptomer begrænset og sammenlignende data vedrørende gavn versus risici på de forskellige strategier savnes.
In Crohn’s disease, experience with re-administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking.
I CRYSTAL var andelen af forsøgspersoner, som oplevede fuldstændig resolution (defineret som 100 % resolution af mindst et target-tophus, og at intet tophus viste progression) på ≥1 target-tophus, højere i gruppen, som blev behandlet med Zurampic 200 mg i kombination med febuxostat, sammenlignet med placebo i kombination med febuxostat, selvom forskellen ikke var statistisk signifikant (26 % sammenlignet med 21 %).
In CRYSTAL, the proportion of subjects who experienced a complete resolution (defined as 100% resolution of at least one target tophus and no single tophus showing progression) of ≥1 target tophus was higher in the group treated with Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat, although the difference was not statistically different (26% compared with 21%).
I CT-AMT-011-02 blev der desuden indsamlet fæces.
In CT-AMT-011- 02 faeces was also collected.
I CURE var anvendelse af clopidogrel forbundet med et aftagende behov for behandling med trombolytika (RR = 43,3 %, CI: 24,3 %; 57,5 %) og GPIIb/IIIa-hæmmere (RR = 18,2 %, CI: 6,5 %; 28,3 %).
The use of clopidogrel in CURE was associated with a decrease in the need for thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
I CURE var anvendelse af clopidogrel forbundet med et aftagende behov for behandling med trombolytika (RR = 43,3 %, CI: 24,3 %; 57,5 %) og GPIIb/IIIa-hæmmere (RRR = 18,2 %, CI: 6,5 %; 28,3 %).
The use of clopidogrel in CURE was associated with a decrease in the need for thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
I CURE var anvendelse af clopidogrel forbundet med et aftagende behov for behandling med trombolytika (RRR = 43,3 %, CI: 24,3 %, 57,5 %) og GPIIb/IIIa-hæmmere (RRR = 18,2 %, CI: 6,5 %, 28,3 %).
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%).
I CURE var anvendelse af clopidogrel forbundet med et aftagende behov for behandling med trombolytika (RRR=43,3 %, CI: 24,3 %, 57,5 %) og GPIIb/IIIa-hæmmere (RRR=18,2 %, CI: 6,5 %, 28,3 %).
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%).
I CURE var der ikke overrepræsentation af større blødninger med clopidogrel plus ASA inden for
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
I CURE var forekomsten af større blødninger med Clopidogrel+ASA dosisafhængig for ASA
In CURE, the major bleeding event rate for Clopidogrel+ASA was dose-dependent on ASA
I CURE var forekomsten af større blødninger med clopidogrel+ASA dosisafhængig for ASA (<100 mg 2,6 %; 100-200 mg: 3,5 %; >200mg: 4,9 %), ligeledes var forekomsten af større blødninger for placebo+ASA (<100 mg: 2,0 %; 100-200 mg: 2,3 %; >200 mg: 4,0 %).
In CURE, the major bleeding event rate for clopidogrel + ASA was dose-dependent on ASA (<100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo + ASA (<100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%).The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months
I CURE, CLARITY og et af kohortestudier (Trenk) blev der ikke observeret nogen øget forekomst af hændelser, baseret på metabolismestatus.
In CURE, CLARITY and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
I CURE, CLARITY, ACTIVE-A og etn af kohortestudierne (Trenk) blev der ikke observeret nogen øget forekomst af hændelser, baseret på metabolisk status.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
I cyklus 1 og 2 gives Empliciti en gang om ugen på dag 1, 8, 15 og 22.
In cycles 1 and 2, Empliciti is administered once weekly on days 1, 8, 15, and 22.
I cyklus 1 til 4 gives Bortezomib Accord to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
In cycles 1 to 4, Bortezomib Accord is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
I cyklus 1 til 4 gives Bortezomib SUN to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
In cycles 1 to 4, Bortezomib SUN is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
I cyklus 1 til 4 gives bortezomib to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
In cycles 1 to 4, bortezomib is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
I cyklus 1 til 4 gives VELCADE to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
In cycles 1 to 4, VELCADE is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
I cyklus 3 og derefter gives Empliciti en gang hver anden uge på dag 1 og 15.
In cycles 3 and beyond, Empliciti is administered once every 2 weeks on days 1 and 15.
I cyklus 5 til 9 gives Bortezomib Accord en gang om ugen på dag 1, 8, 22 og 29.
In cycles 5 to 9, Bortezomib Accord is administered once weekly on days 1, 8, 22 and 29.
I cyklus 5 til 9 gives Bortezomib SUN en gang om ugen på dag 1, 8, 22 og 29.
In cycles 5 to 9, Bortezomib SUN is administered once weekly on days 1, 8, 22 and 29.
I cyklus 5 til 9 gives bortezomib én gang om ugen på dag 1, 8, 22 og 29.
In cycles 5 to 9, bortezomib is administered once weekly on days 1, 8, 22 and 29.
I cyklus 5 til 9 gives VELCADE en gang om ugen på dag 1, 8, 22 og 29.
In cycles 5 to 9, VELCADE is administered once weekly on days 1, 8, 22 and 29.
I dagene efter du begynder med behandlingen, kan din læge øge din dosis af Suboxone i henhold til dine behov.
During the days after you start treatment, your doctor may increase the dose of Suboxone you take according to your needs.
I dasatinib-armen opnåede 93% af patienterne CHR inden crossover og i imatinib-armen opnåede 82% af patienterne CHR inden crossover.
Ninety-three percent of patients in the dasatinib arm and 82% of patients in the imatinib arm achieved a CHR prior to crossover.
I data sammenlagt fra tre studier fik 39 patienter med recidiveret eller kemoterapi-resistent, udbredt sygdom (enkeltlæsion  10 cm i diameter), lavmalignt eller follikulært B-celle NHL 375 mg/m2 MabThera som intravenøs infusion ugentligt i fire doser.
In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion  10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of MabThera as intravenous infusion weekly for four doses.
I de 144-ugers kliniske studier med Stribild seponerede 13 (1,9 %) af personerne i Stribild-gruppen (n = 701) og 8 (2,3 %) af personerne i gruppen med ATV/r+FTC/TDF (n = 355) studiemedicinen på grund af nyrebivirkninger.
In the clinical studies of Stribild over 144 weeks, 13 (1.9%) subjects in the Stribild group (n = 701) and 8 (2.3%) subjects in the ATV/r+FTC/TDF group (n = 355) discontinued study drug due to a renal adverse reaction.
I de 20 integrerede placebokontrollerede undersøgelser blev der iagttaget stigninger i leveraminotransferaser > 3 gange den normale øvre grænse (ULN) hos 11,2% af de patienter, der fik bosentan mod 2,4% af de patienter, der fik placebo.
In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases  3 times the upper limit of normal (ULN) were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients.
I de 20 integrerede placebokontrollerede undersøgelser blev der iagttaget stigninger i leveraminotransferaser på > 3 gange den normale øvre grænse (ULN) hos 11,2% af de patienter, der fik bosentan mod 2,4% af de patienter, der fik placebo.
In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases  3 times the upper limit of normal (ULN) were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients.
I de 24 ugers forsøgsbehandling med Incruse var den gennemsnitlige (SD) ændring i forhold til baseline i antal pust af anfaldsmedicin (salbutamol) over behandlingsperioden på 24 uger -1,4 (0,20) for placebo og -1,7 (0,16) for Incruse (forskel = -0,3, 95 % CI: -0,8, 0,2, p = 0,276).
In the 24-week study treatment with Incruse, the mean (SD) change from baseline in the number of puffs of rescue salbutamol over the 24-week treatment period was -1.4 (0.20) for placebo and -1.7 (0.16) for Incruse (Difference = -0.3; 95% CI: -0.8, 0.2, p=0.276).
I de 3 aktivt-kontrollerede studier blev der rapporteret en højere frekvens af MI hos patienter, der fik dabigatranetexilat, end hos dem, der fik warfarin; i de to korterevarende studier RE-COVER and RE- COVER II henholdsvis 0,4 % vs.
In the three active controlled studies, a higher rate of MI was reported in patients who received dabigatran etexilate than in those who received warfarin: 0.4% vs.
I de 3 aktivt-kontrollerede studier rapporteredes en højere frekvens af MI hos patienter, der fik dabigatranetexilat, end hos patienter, der fik warfarin: 0,4 % vs.
In the three active controlled studies, a higher rate of MI was reported in patients who received dabigatran etexilate than in those who received warfarin: 0.4% vs.
I de 3 studier (et fase 2- og to fase 3-studier, Studie 1 og Studie 2) var den kumulative hyppighed af PTLD højere hos belatacept-behandlede patienter ved den anbefalede dosering (LI) (1,3%; 6/472) end i ciclosporin-gruppen (0,6%; 3/476) og den var højest i belatacept MI-gruppen (1,7%; 8/477).
In the 3 studies (one phase 2 and two phase 3 studies, Study 1 and Study 2), the cumulative frequency of PTLD was higher in belatacept treated patients at the recommended dosing regimen (LI) (1.3%; 6/472) than in the ciclosporin group (0.6%; 3/476), and was highest in the belatacept MI group (1.7%; 8/477).
I de 6-måneders kontrollerede studier blev der set fald i trombocyttal til under 100 x 103/l hos 1,7 % af de patienter, der fik tocilizumab 8 mg/kg plus DMARDs, sammenlignet med < 1 % hos de patienter, der fik placebo plus DMARDs.
In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μl occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.
I de 6-måneders kontrollerede studier blev der set fald i trombocyttal til under 100 x 103/µl hos 1,7 % af de patienter, der fik tocilizumab 8 mg/kg plus DMARDs, sammenlignet med < 1 % hos de patienter, der fik placebo plus DMARDs.
In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μl occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.
I de 8 gennemførte undersøgelser indgik der 46 unikke pædiatriske forsøgspersoner, som blev indrulleret og eksponeretfor Cinryze (2-5 år, n=3; 6-11 år, n=17; 12-17 år, n=26).
Across 8 completed clinical studies, there were 46 unique paediatric subjects enrolled and exposed to Cinryze (2-5 years, n=3; 6-11 years, n=17; 12-17 years, n=26).
I de afsluttede fase III-studier observeredes det, at omtrent 90 % af patienterne kunne forblive på vedligeholdelsesdosis 20 µg Lyxumia én gang dagligt ved afslutning af den 24-ugers behandlings- periode.
In the completed Phase III studies, it was observed that approximately 90% of the patients were able to remain on the once daily maintenance dose of 20 mcg Lyxumia at the end of the main 24-week treatment period.
I de andre to undersøgelser (516 patienter) så man på, hvilken virkning Xyrem havde på den overdrevne søvntrang i dagtimerne og andre symptomer på narkolepsi, når det enten blev taget alene eller som tillægsbehandling til patientens eksisterende dosis af modafinil (et stimulerende lægemiddel til behandling af narkolepsi).
The other two studies (516 patients) examined the effects of Xyrem on excessive daytime sleepiness and other symptoms of narcolepsy, either taken alone or as an add-on to the patient’s existing dose of modafinil (a stimulant medicine used to treat narcolepsy).
I de andre to undersøgelser blev ritonavir-boostet Prezista sammenlignet med andre proteasehæmmere, der var valgt på grundlag af patientens tidligere behandlinger og forventede respons, hos i alt 628 patienter, som tidligere havde fået mange forskellige lægemidler mod hiv.
The other two studies compared ritonavir-boosted Prezista with other protease inhibitors chosen on the basis of the patient’s previous treatments and predicted response, in a total of 628 patients who had taken many anti-HIV medicines in the past.
I de andre to undersøgelser blev Telzir sammenlignet med lopinavir (en anden proteasehæmmer), hvor begge var forstærket med ritonavir.
The other two studies compared Telzir with lopinavir (another protease inhibitor), both of which were boosted with ritonavir.
I de andre to undersøgelser havde 85 % af patienterne ingen tilbagefald.
In the other two studies, 85% of patients had no relapses.
I de andre tre undersøgelser med et aktivt sammenligningsstof var der ingen forskel i resultaterne mellem patienter, som tog Thymanax, og dem, der tog placebo.
In the other three studies, which did include an active comparator, there were no differences in scores between the patients taking Thymanax and those taking placebo.
I de andre tre undersøgelser med et aktivt sammenligningsstof var der ingen forskel i resultaterne mellem patienter, som tog Valdoxan, og dem, der tog placebo.
In the other three studies, which did include an active comparator, there were no differences in scores between the patients taking Valdoxan and those taking placebo.
I de arterier, der forsyner lungerne (lungeemboli)
In the arteries supplying the lungs (pulmonary embolism)
I de begrænsede tilgængelige data fandtes der intet bevis for, at der var en markant etnisk forskel i olaparibs farmakokinetik mellem japanske og kaukasiske patienter.
In the limited data available, there was no evidence of a marked ethnic difference in the PK of olaparib between Japanese and Caucasian patients.
I de cellulære anti-proliferationsanalyser var hæmmende koncentration 50 (IC50) mod V600-muterede cellelinjer (V600E-,V600R-, V600D- og V600K-muterede cellelinjer) fra 0,016 til 1,131 µM, hvorimod IC50 mod BRAF vildtype-cellelinjer var henholdsvis 12,06 og 14,32 µM.
In cellular anti-proliferation assays the inhibitory concentration 50 (IC50) against V600 mutated cell lines (V600E, V600R, V600D and V600K mutated cell lines) ranged from 0.016 to 1.131 M whereas the IC50 against BRAF wild type cell lines were 12.06 and 14.32 M, respectively.
I de dobbeltblinde, placebokontrollerede undersøgelser blev 529 patienter behandlet med rasagilin 1 mg dagligt i 212 patientår, og 539 patienter fik placebo i 213 patientår.
In the double blind placebo controlled studies, 529 patients were treated with rasagiline 1 mg/day for 212 patient years and 539 patients received placebo for 213 patient years.
I de efterfølgende 63 uger skal du anvende IL-2 og Ceplene daglig i 3 uger efterfulgt af en 6 ugers pause (overhovedet ingen behandlinger).
For the following 63 weeks: you will use IL-2 and Ceplene daily for 3 weeks, followed by a 6 week break (no treatment at all).
I de efterfølgende serier bør en H1-antagonist (f.eks. diphenhydramin) gives intravenøst 30-60 minutter forud for hver dosis af olaratumab.
For subsequent cycles, premedication with an H1 antagonist (e.g., diphenhydramine) should be given intravenously 30–60 minutes prior to each dose of olaratumab.